@article{SirenLettsFeuerstein1988,
  author    = {Sir{\´e}n, Anna-Leena and Letts, G. and Feuerstein, G.},
  title     = {N-Acetyl-leukotriene E\(_4\) is a potent constrictor of rat mesenteric vessels},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-63196},
  year      = {1988},
  abstract  = {N-Acetyl-leukotriene E\(_4\) administered to conscious freely moving rats produced a dose-dependent vasoconstriction in the mesenteric vessels which led to profound reduction of blood flow to the gut. Renal and hindquarter blood flow and vascular resistance were not affected even by high doses of N-acetyl-leukotriene E\(_4\) . N-Acetyl-leukotriene E\(_4\) was 10-fold more potent than the thromboxane analog U-46619 and 1000-fold more potent than prostaglandin F\(_{2a}\) but 2-5-fold less potent than leukotriene D\(_4\)/E\(_4\) to induce mesenteric vasoconstriction. These data indicatc that N-acetylleukotriene E\(_4\) is a biologically active metabolite of peptide leukotrienes, and might play a role in cardiovascular derangements mediated by leukotrienes.},
  subject      = {Neurobiologie},
  language  = {en}
}
@article{FeuersteinSiren1988,
  author    = {Feuerstein, G. and Sir{\´e}n, Anna-Leena},
  title     = {Mesenteric vascular responses to i.v. administration of lipoxin A\(_4\) and lipoxin B\(_4\) in the conscious rat},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-63200},
  year      = {1988},
  abstract  = {Lipoxin A (LXA\(_4\)) and lipoxin B\(_4\)(LXB\(_4\)) are newly discovered lipoxygenase-interacting products of leukocytes which might have a role in cardiovascular events associated with anaphylaxis. We have tested this possibility by systemic administration of both LXA\(_4\) and LXB\(_4\) to the conscious rat while monitaring systemic and regional hemodynamic changes. LXA\(_4\) and' LXB\(_4\) (l-100 pg/kg) produced dose-dependent constriction of the mesenteric vessels, up to + 123±23\% and +50±9\% for LXA\(_4\)/B\(_4\) , respectively. Dose-related changes were not observed in arterial blood pressure, heart rate, renal (LXB\(_4\)) and hindquarter blood ftow. We suggest that LXA\(_4\) and LXB\(_4\) might affect selective vascular beds, such as the mesenteric vessels, and contribute to variations in blood flow in specific pathophysiological states.},
  subject      = {Neurobiologie},
  language  = {en}
}
@article{Siren1988,
  author    = {Sir{\´e}n, Anna-Leena},
  title     = {Cardiovascular pharmacology of thyrotropin releasing hormone},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-63214},
  year      = {1988},
  subject      = {Neurobiologie},
  language  = {en}
}
@article{FeuersteinSiren1988,
  author    = {Feuerstein, G. and Sir{\´e}n, Anna-Leena},
  title     = {Hypothalamic µ-receptors in the cardiovascular control: a review},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-63228},
  year      = {1988},
  abstract  = {The endogenous opioid system includes three major families of peptides [22): dynorphins (derived from pre-proenkephalin B); endorphins (derived from pre-proopiomelanocortin) and enkephalins (derived from pre-proenkephalin A). Multiple species of opioid peptides are derived from these major precursors and many of them possess potent cardiovascular properties. Multiple forms of opioid receptors have been defined in the central nervous system. Although the relationship of these receptors to the multiple actions of the opioid systems is not weil understood, some predications can be made: in vitro the dynorphin-related peptidesbind preferentially to kappa-opioid receptors; the enkephalins bind preferentially to delta and JL-opioid receptors and while beta-endorphin binds to mu- and delta-, but not to kappa-opioid receptors. While littleis known on the roJe ofthe opioid system in normal cardiovascular regulation, it has become clear that cardiovascular stress situations substantially modify the activity ofthe endogenous opioid system. This review focuses on the mu-opioid system in the hypothalamus with special emphasis on its potential roJe in cardiovascular control of both normal and pathophysiologic states.},
  subject      = {Neurobiologie},
  language  = {en}
}
@article{SirenFeuerstein1988,
  author    = {Sir{\´e}n, Anna-Leena and Feuerstein, G.},
  title     = {Cardiovascular effects of rat calcitonin gene-related peptide in the conscious rat},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-63236},
  year      = {1988},
  subject      = {Neurobiologie},
  language  = {en}
}
@article{FeuersteinLeaderSirenetal.1987,
  author    = {Feuerstein, G. and Leader, P. and Sir{\´e}n, Anna-Leena and Braquet, P.},
  title     = {Protective effect of PAF-acether antagonist, BN 52021, in trichothecen toxicosis},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-63244},
  year      = {1987},
  abstract  = {Trichothecenes are mycotoxins which produce Iethai toxicosis in humans and animals, yet no adequate therapeutic regimen has been developed. This study provides evidence that the selective platelet activating factor (PAF) antagonist, BN 52021 (5-15 mg/kg i.v.) can prolong the survival of conscious rats exposed to a highly Iethai T -2 toxicosis. These data also suggest that P AF is an important mediator of this unique toxicosis.},
  subject      = {Neurobiologie},
  language  = {en}
}
@article{LabrooCohenLozovskyetal.1987,
  author    = {Labroo, V. M. and Cohen, L. A. and Lozovsky, D. and Sir{\´e}n, Anna-Leena and Feuerstein, G.},
  title     = {Dissociation of the cardiovascular and prolactin-releasing activities of TRH by histidine replacement},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-63253},
  year      = {1987},
  abstract  = {No abstract available},
  subject      = {Neurobiologie},
  language  = {en}
}
@misc{FeuersteinSiren1987,
  author    = {Feuerstein, G. and Sir{\´e}n, Anna-Leena},
  title     = {Opioid peptides: A role in hypertension? [Brief Review]},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-63262},
  year      = {1987},
  abstract  = {This review is an attempt to highlight evidence that may implicate the endogenaus opioid system in the pathogenesis of hypertension in humans. The evidence raised includes biochemical, physiological, pharmacological, and behavioral studies con~ucted in in vitro andin vivo systems, experimental models of hypertension, and hornans with essential hypertension. While the compelling biochemical and pharmacological evidence in experimental animals clearly shows the presence of opioid peptides and their receptors in strategic sites of cardiovascular control and potent cardiovascular response to opioid peptides, opioid antagonists show no consistent blockade or reversal of hypertension in experimental animals or humans. One possible explanation for this phenomenon could be the vast redundancy in systems regulating blood pressure (i.e., the blockade ofone system stillleaves many other systerils fully able to rapidly offset the eliminated system). Regarding the opioid system, the situation is much more complex, since some opioid receptors (\(\mu\)-type) niediate pressor responses, while other receptors (\(\kappa\)type) mediate depressor responses. Therefore, nonselective opioid receptor antagonists (e.g., naloxone), which block both types ofreceptors, can be devoid ofany cardiovascular activity, while a selective \(\mu\)-receptor antagonist or a selective arid potent \(\kappa\)-receptor agonist may produce the desired antihypertensive elfect. A combination of both actions (i.e., a drug that is both \(\mu\)antagonist and a \(\kappa\)antagonist) might be even more advantageous. Until such compounds are developed, this hypothesis will be hard to prove.},
  subject      = {Neurobiologie},
  language  = {en}
}
@article{PaakkariNurminenSiren1986,
  author    = {Paakkari, I. and Nurminen, M-L. and Sir{\´e}n, Anna-Leena},
  title     = {Cardioventilatory effects of TRH in anesthetized rats: role of the brainstem},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-63277},
  year      = {1986},
  abstract  = {Cardioventilator responses were studied in anaesthetized rats after injections of TRH into either the lateral (i.c.v. lat) or the fourth (i.c.v. IV) cerebral ventricles. TRH induced a morerapid hypertensive effect i.c.v. IV than i.c.v. lat. Blocking of the cerebral aqueduct abolished the hypertensive and tachypnoeic effects of TRH i.c.v. lat but not those of TRH i.c.v. IV. It is concluded that TRH increased blood pressure and ventilation rate via brain stem structures close to the fourtli ventricle.},
  subject      = {Neurobiologie},
  language  = {en}
}
@article{SirenPowellFeuerstein1986,
  author    = {Sir{\´e}n, Anna-Leena and Powell, E. and Feuerstein, G.},
  title     = {Thyrotropin releasing hormone in hypovolemia: a hemodynamic evaluation in the rat},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-63288},
  year      = {1986},
  abstract  = {ln the present study the effects of thyrotropin releasing hormone (TRH) and its stable analogue, CG3703, on cardiac output (thermodilution, Cardiomax) and regional blood flow (BF; directional pulsed Doppler technique) were investigated in hypovolemic hypotension in the rat. In urethan-anesthetized rats TRH (0.5 or 2 mg/ kg ia) or CG3703 (0.05 or 0.5 mg/kg ia) reversed the bleeding (27\% of the blood volume)-induced decreases in mean arterial ...},
  subject      = {Neurobiologie},
  language  = {en}
}